NASDAQ:VALN Valneva (VALN) Stock Price, News & Analysis $8.24 +0.38 (+4.76%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Valneva Stock (NASDAQ:VALN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Valneva alerts:Sign Up Key Stats Today's Range$7.90▼$8.3250-Day Range$5.56▼$7.8752-Week Range$3.62▼$8.66Volume70,958 shsAverage Volume59,234 shsMarket Capitalization$701.57 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingBuy Company Overview Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. Read More Valneva Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreVALN MarketRank™: Valneva scored higher than 54% of companies evaluated by MarketBeat, and ranked 952nd out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingValneva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageValneva has only been the subject of 1 research reports in the past 90 days.Read more about Valneva's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Valneva are expected to decrease in the coming year, from $0.13 to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Valneva is -6.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Valneva is -6.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioValneva has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Valneva's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.03% of the float of Valneva has been sold short.Short Interest Ratio / Days to CoverValneva has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Valneva has recently decreased by 99.97%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldValneva does not currently pay a dividend.Dividend GrowthValneva does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.03% of the float of Valneva has been sold short.Short Interest Ratio / Days to CoverValneva has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Valneva has recently decreased by 99.97%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.30 News SentimentValneva has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Valneva this week, compared to 4 articles on an average week.Search Interest1 people have searched for VALN on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Valneva to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Valneva insiders have not sold or bought any company stock.Percentage Held by Insiders14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.39% of the stock of Valneva is held by institutions.Read more about Valneva's insider trading history. Receive VALN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter. Email Address VALN Stock News HeadlinesVALNEVA Declaration of shares and voting rights: July 31, 2025August 6 at 6:26 AM | finance.yahoo.comAGC Biologics’ Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva’s Tetravalent Shigella Vaccine CandidateJuly 29, 2025 | finance.yahoo.comFuturist Eric Fry says it will be a “Summer of Surge” for these three stocksWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strategy: Sell This, Buy That. In his newest presentation, Eric reveals 7 new trade ideas—pairing overhyped, vulnerable stocks with lesser-known opportunities showing real upside. These contrarian picks come from the same approach that helped him beat Wall Street legends 10-to-1 in Portfolios with Purpose.August 6 at 2:00 AM | InvestorPlace (Ad)Valneva's chikungunya vaccine suspension gets lifted for older adultsJuly 11, 2025 | msn.comValneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in ElderlyJuly 11, 2025 | globenewswire.comEurope lifts restriction on Valneva's chikungunya vaccine for elderly adultsJuly 11, 2025 | reuters.comValneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL SeqirusJune 26, 2025 | globenewswire.comValneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidanceJune 25, 2025 | globenewswire.comSee More Headlines VALN Stock Analysis - Frequently Asked Questions How have VALN shares performed this year? Valneva's stock was trading at $4.37 at the beginning of the year. Since then, VALN shares have increased by 89.9% and is now trading at $8.30. How were Valneva's earnings last quarter? Valneva SE Sponsored ADR (NASDAQ:VALN) issued its earnings results on Wednesday, May, 7th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.27. The business had revenue of $51.79 million for the quarter, compared to analyst estimates of $41.80 million. Valneva had a negative trailing twelve-month return on equity of 43.05% and a negative net margin of 43.08%. Read the conference call transcript. When did Valneva IPO? Valneva (VALN) raised $99 million in an initial public offering (IPO) on Thursday, May 6th 2021. The company issued 3,500,000 shares at $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. served as the underwriters for the IPO. How do I buy shares of Valneva? Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Valneva own? Based on aggregate information from My MarketBeat watchlists, some other companies that Valneva investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/07/2025Today8/06/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VALN CIK1836564 Webvalneva.com Phone33-2-28-07-37-10FaxN/AEmployees700Year FoundedN/APrice Target and Rating Average Price Target for Valneva$15.50 High Price Target$17.00 Low Price Target$14.00 Potential Upside/Downside+97.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.19) Trailing P/E RatioN/A Forward P/E Ratio60.54 P/E GrowthN/ANet Income-$13.25 million Net Margins-43.08% Pretax Margin-6.77% Return on Equity-43.05% Return on Assets-16.23% Debt Debt-to-Equity Ratio0.92 Current Ratio2.70 Quick Ratio2.12 Sales & Book Value Annual Sales$183.52 million Price / Sales3.65 Cash Flow$0.10 per share Price / Cash Flow76.76 Book Value$2.41 per share Price / Book3.27Miscellaneous Outstanding Shares85,090,000Free Float72,406,000Market Cap$669.66 million OptionableNot Optionable Beta1.77 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:VALN) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.